Attached files
file | filename |
---|---|
10-Q - FORM 10-Q - Adhera Therapeutics, Inc. | d237565d10q.htm |
EX-32.2 - SECTION 906 PRINCIPAL FINANCIAL OFFICER CERTIFICATION - Adhera Therapeutics, Inc. | d237565dex322.htm |
EX-32.1 - SECTION 906 PRINCIPAL EXECUTIVE OFFICER CERTIFICATION - Adhera Therapeutics, Inc. | d237565dex321.htm |
EXCEL - IDEA: XBRL DOCUMENT - Adhera Therapeutics, Inc. | Financial_Report.xls |
EX-31.1 - SECTION 302 PRINCIPAL EXECUTIVE OFFICER CERTIFICATION - Adhera Therapeutics, Inc. | d237565dex311.htm |
Exhibit 31.2
PRINCIPAL FINANCIAL OFFICER CERTIFICATION
REQUIRED BY RULES 13A-14 AND 15D-14 UNDER THE SECURITIES EXCHANGE ACT OF 1934,
AS AMENDED
I, Philip C. Ranker, certify that:
1. I have reviewed this quarterly report on Form 10-Q of Marina Biotech, Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrants other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and we have:
a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b) designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c) evaluated the effectiveness of the registrants disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures as of the end of the period covered by this report based on such evaluation;
d) disclosed in this report any change in the registrants internal control over financial reporting that occurred during the registrants most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrants internal control over financial reporting; and
5. The registrants other certifying officer and I have disclosed, based on our most recent evaluation, to the registrants auditors and the audit committee of registrants board of directors (or persons performing the equivalent function):
a) all significant deficiencies in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrants ability to record, process, summarize and report financial information; and
b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrants internal control over financial reporting.
Date: November 10, 2011
By: | /s/ Philip C. Ranker | |||
Name: | Philip C. Ranker | |||
Title: | Interim Chief Financial Officer | |||
(Principal Financial Officer and Principal Accounting Officer) |